On December 7, 2022

Qurgen received FDA IND approval (IND #152226) for the Phase I clinical trial of SON-DP, a first-in-human and first-in-class transcription factor anti-cancer protein drug that leads to a breakthrough cell-conversion cancer therapy for all solid tumors.